Nicotinamide Phosphoribosyltransferase/Visfatin Does Not Catalyze Nicotinamide Mononucleotide Formation in Blood Plasma
Open Access
- 3 August 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (8), e22781
- https://doi.org/10.1371/journal.pone.0022781
Abstract
Nicotinamide (Nam) phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in mammalian NAD synthesis, catalyzing nicotinamide mononucleotide (NMN) formation from Nam and 5-phosphoribosyl 1-pyrophosphate (PRPP). NAMPT has also been described as an adipocytokine visfatin with a variety of actions, although physiological significance of this protein remains unclear. It has been proposed that possible actions of visfatin are mediated through the extracellular formation of NMN. However, we did not detect NMN in mouse blood plasma, even with a highly specific and sensitive liquid chromatography/tandem mass spectrometry. Furthermore, there is no or little ATP, the activator of NAMPT, in extracellular spaces. We thus questioned whether visfatin catalyzes the in situ formation of NMN under such extracellular milieus. To address this question, we here determined Km values for the substrates Nam and PRPP in the NAMPT reaction without or with ATP using a recombinant human enzyme and found that 1 mM ATP dramatically decreases Km values for the substrates, in particular PRPP to its intracellular concentration. Consistent with the kinetic data, only when ATP is present at millimolar levels, NAMPT efficiently catalyzed the NMN formation at the intracellular concentrations of the substrates. Much lower concentrations of Nam and almost the absence of PRPP and ATP in the blood plasma suggest that NAMPT should not efficiently catalyze its reaction under the extracellular milieu. Indeed, NAMPT did not form NMN in the blood plasma. From these kinetic analyses of the enzyme and quantitative determination of its substrates, activator, and product, we conclude that visfatin does not participate in NMN formation under the extracellular milieus. Together with the absence of NMN in the blood plasma, our conclusion does not support the concept of “NAMPT-mediated systemic NAD biosynthesis.” Our study would advance current understanding of visfatin physiology.Keywords
This publication has 34 references indexed in Scilit:
- Pathways and Subcellular Compartmentation of NAD Biosynthesis in Human CellsPublished by Elsevier BV ,2011
- Nampt: linking NAD biology, metabolism and cancerTrends in Endocrinology & Metabolism, 2009
- The NAD World: A New Systemic Regulatory Network for Metabolism and Aging—Sirt1, Systemic NAD Biosynthesis, and Their ImportanceCell Biochemistry and Biophysics, 2009
- Extracellular Nampt Promotes Macrophage Survival via a Nonenzymatic Interleukin-6/STAT3 Signaling MechanismPublished by Elsevier BV ,2008
- Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotideCardiovascular Research, 2008
- Weak Coupling of ATP Hydrolysis to the Chemical Equilibrium of Human Nicotinamide PhosphoribosyltransferaseBiochemistry, 2008
- Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokineClinical Science, 2008
- Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic EnzymeCell Metabolism, 2007
- Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of InsulinScience, 2005
- Evidence for a physiologically active nicotinamide phosphoribosyl transferase in cultured human fibroblastsBiochemical and Biophysical Research Communications, 1982